产品详情
简单介绍：
重组大鼠干扰素-γ蛋白与其它公司提供的重组蛋白不同，rRtIFN-γ蛋白产品为采用CFS的无细胞麦胚蛋白合成系统表达出来的重组蛋白，可表达出对细胞有毒性、易被蛋白酶降解的蛋白；并获得具有良好的可溶性，并有翻译后修饰、从而部分具有功能的蛋白.同时独有的全自动蛋白纯化技术则简便高效，将蛋白纯化过程中对蛋白的损伤降低到*小程度.重组大鼠干扰素-γ蛋白（全长序列）产品可用于Western Blot验证、抗体制备、蛋白检测、ELISA等试验中.
详情介绍：
重组大鼠干扰素-γ蛋白
| Species | Rat |
| Accession | P01581 |
| GeneID | 25712 |
| Source | Escherichia coli. |
| Molecular Weight | 重组大鼠干扰素-γ蛋白Approximately 15.5 kDa, a single non-glycosylated polypeptide chain containing 134 amino acids. |
| Quantity | 20µg/100µg/1000µg |
| AA Sequence | QGTLIESLES LKNYFNSSSM DAMEGKSLLL DIWRNWQKDG NTKILESQII SFYLRLFEVL KDNQAISNNI SVIESHLITN FFSNSKAKKD AFMSIAKFEV NNPQIQHKAV NELIRVIHQL SPESSLRKRK RSRC |
| Purity | > 97 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | 重组大鼠干扰素-γ蛋白Fully biologically active when compared to standard. The ED50as determined by an anti-viral assay using murine L929 cells infected with encephalomyocarditis (EMC) virus is less than 0.1 ng/ml, corresponding to a specific activity of > 1.0 × 107IU/mg. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | Lyophilized from a 0.2 µm filtered concentrated solution in 1 × PBS, pH 7.4, 1 mM DTT, 5 % Trehalose and 0.05 % Tween-80. |
| Endotoxin | Less than 0.1 EU/µg of rRtIFN-γ as determined by LAL method. |
| Reconstitution | 重组大鼠干扰素-γ蛋白We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in 10 mM HAc to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重组大鼠干扰素-γ蛋白 | |
| SDS-PAGE |  |
| Reference | 1. Wang H, Ruan Z, Wang Y, et al. 2008. Mol Immunol, 45: 1548-56. 2. Kopinski P, Przybylski G, Jarzemska A, et al. 2007. Pol Merkur Lekarski, 23: 15-21. 3. Pennino D, Bhavsar PK, Effner R, et al. 2012. J Allergy Clin Immunol, 4. Hibi M, Hachimura S, Ise W, et al. 2003. Cytotechnology, 43: 49-55. |
| Background | Interferon-gamma (IFN-γ), also known as Type II interferon or immune interferon, is a cytokine produced primarily by T-lymphocytes and natural killer cells. The protein shares no significant homology with IFN-β or the various IFN-α family proteins. Mature IFN-γ exists as noncovalently-linked homodimers. It shares high sequence indentity with mouse IFN-γ (86 %). IFN-γ was originally characterized based on its antiviral activities. The protein also exerts antiproliferative, immunoregulatory and proinflammatory activities and is thus important in host defense mechanisms. IFN-γ induces the production of cytokines, upregulates the expression of class I and II MHC antigens, Fc receptor and leukocyte adhesion molecules. It modulates macrophage effector functions, influences isotype switching and potentiates the secretion of immunoglobulins by B cells. Additionally, IFN-γ augments TH1 cell expansion and may be required for TH1 cell differentiation. |
